Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Sep 2025 value amounting to $849.2 million.

  • Maravai Lifesciences Holdings' Liabilities and Shareholders Equity fell 33.57% to $849.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 34.31%. This contributed to the annual value of $1.0 billion for FY2024, which is 32.22% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Liabilities and Shareholders Equity stood at $849.2 million for Q3 2025, which was down 5.33% from $897.0 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Liabilities and Shareholders Equity ranged from a high of $2.3 billion in Q1 2023 and a low of $849.2 million during Q3 2025.
  • In the last 3 years, Maravai Lifesciences Holdings' Liabilities and Shareholders Equity had a median value of $1.4 billion in 2024 and averaged $1.5 billion.
  • In the last 5 years, Maravai Lifesciences Holdings' Liabilities and Shareholders Equity soared by 51.15% in 2022 and then tumbled by 43.63% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Liabilities and Shareholders Equity (Quarterly) stood at $1.9 billion in 2021, then grew by 18.98% to $2.3 billion in 2022, then crashed by 34.83% to $1.5 billion in 2023, then plummeted by 32.22% to $1.0 billion in 2024, then plummeted by 33.57% to $849.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $849.2 million for Q3 2025, versus $897.0 million for Q2 2025 and $959.8 million for Q1 2025.